China approves first medical BCI in 2026 as global trial volunteers exceed cumulative prior decade

Trial enrollment accelerated sharply after 2024. Registries show volunteer counts rising from under 50 active participants worldwide in 2023 to several hundred by mid-2026. China issued the first national medical approval for a BCI system this year, citing safety data from 32-patient cohorts. Hardware advances now include higher channel counts and wireless telemetry, enabling longer sessions without percutaneous connectors.

Operational metrics from Harrell's deployment record 12-hour daily use with stable signal quality over nine months. Output includes email, document editing, and voice synthesis at 15-20 words per minute. These figures exceed 2023 lab benchmarks by 2-3x. Parallel reports from Synchron and Blackrock arrays indicate similar uptime gains once calibration routines incorporate patient-specific drift correction.

The shift moves BCI from episodic research sessions to continuous daily tooling. This compresses the boundary between assistive devices and general input layers, raising questions about data ownership, signal security, and downstream effects on professional skill retention. Deployment records now track integration with existing productivity stacks rather than isolated lab tasks.

Next phase centers on regulatory expansion beyond ALS. Two additional manufacturers filed pivotal trial protocols with the FDA in Q2 2026 targeting stroke and spinal injury cohorts. Volume thresholds for insurance coverage discussions sit at 200 patients per indication.